(MedPage Today) -- Treatment with a combination of teriparatide (Forteo) plus denosumab (Prolia) led to greater increases in bone mineral density in postmenopausal women with osteoporosis than either agent alone, a randomized trial showed.
Closing out the day... Stocks were virtually unchanged Monday as the S&P 500 and Nasdaq managed to eke out gains while the Dow saw a small loss. Among the high-volume stocks today American International Group (AIG), Occidental Petroleum Corp (OXY)...
Looking at the universe of stocks we cover at Dividend Channel, on 5/14/13, Eli Lilly & Co. (NYSE: LLY) will trade ex-dividend, for its quarterly dividend of $0.49, payable on 6/10/13. As a percentage of LLY's recent stock price of $54.25, this...
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Lilly+%28LLY%29+to+Halt+Enzastaurin+Production+Following+Phase+III%3B+Sees+Charge/8325772.html for the full story.
Eli Lilly and Co (NYSE: LLY) closed Tuesday's trading session at $54.17. In the past year, the stock has hit a 52-week low of $39.93 and 52-week high of $58.41. Eli Lilly (LLY) stock has been showing support around $53.46 and resistance in the...
Eli Lilly Chairman and CEO John Lechleiter is scheduled for surgery for a dilated aorta on Monday and will hand the CEO reins over to CFO Derica Rice as he recovers. If all goes well, he'll be back on the job later this summer, the company said.
Salesforce cuts are coming down at Eli Lilly, and 40% of its U.S. sales force will be out. According to the company, the drugmaker sent a state Warn Notice to 1,624 sales positions, of which about 1,000 will be let go.
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Eli+Lilly+%28LLY%29+CEO+Lechleiter+to+Take+Scheduled+Medical+Leave/8308968.html for the full story.